Breaking News

Lilly Licenses Camurus’ FluidCrystal Technology for Long-Acting GLP-1s

Lilly to pay $290 million upfront and as much as $580 million in sales-based milestones and royalties.

Camurus and Lilly have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic products based on Camurus’ FluidCrystal technology. The agreement includes up to four Lilly drug compounds selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and an option to include amylin receptor agonists. Ca...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters